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On 31 May 2013, the first case of Middle East 
Respiratory Syndrome Coronavirus (MERS-CoV) infec-
tion in Italy was  laboratory confirmed in a previously 
healthy adult man, who developed pneumonia with 
moderate respiratory distress after returning from a 
holiday in Jordan. Two secondary cases were identified 
through contact tracing, among family members and 
colleagues who had not previously travelled abroad. 
Both secondary cases developed mild illness. All three 
patients recovered fully.
On 31 May 2013, the National Influenza Centre at the 
Istituto Superiore Sanità (NIC-ISS) in Rome, Italy, 
confirmed the first case of Middle East Respiratory 
Syndrome Coronavirus (MERS-CoV) infection in a 
patient, hospitalised in Florence (Tuscany region), 
Italy, who had just spent a vacation in Amman, Jordan. 
Two secondary cases of MERS-CoV were subsequently 
detected among close contacts. We here report the 
public health investigation carried out and the identi-
fication and follow-up of the three patients’ contacts.
Index case
The index case was a previously healthy man in his 
mid-40s who had returned to Florence on 25 May 2013, 
following a 40-day holiday in Jordan (Figure). The 
patient developed influenza-like symptoms the previ-
ous day, while in Jordan, and was symptomatic on the 
flight back to Italy and while back at work in a hotel 
on 27 May.  On 28 May, because of worsening symp-
toms, he visited the emergency room of a local hos-
pital (Hospital A) in Florence and was admitted later 
the same day to the Infectious and Tropical Diseases 
Unit of a second hospital (Hospital B), in the same city. 
His symptoms at that time were fever (38 °C), cough 
and difficult breathing. A chest radiograph revealed 
signs of pneumonia, with bilateral lung infiltrates. The 
following day, testing for MERS-CoV was carried out 
(real-time polymerase chain reaction (PCR) to detect 
the regions upstream of the E gene (upE region)) on 
upper respiratory samples (nasopharyngeal swabs) at 
the Regional reference laboratory for Influenza at the 
University of Florence and MERS-CoV infection was 
diagnosed. This result was confirmed by the National 
Influenza Centre [1]. 
On 29 May, as soon as the clinicians began to suspect 
a MERS-CoV infection, the staff of Hospital B complied 
with all infection control procedures, according to the 
Health Protection Agency (HPA) (now Public Health 
England) infection control advice for suspected or 
confirmed novel coronavirus cases [2]. In particular, 
the patient was isolated in a negative-pressure room 
and staff wore protective clothing and performed hand 
hygiene. Attempts were made at the Regional reference 
laboratory for Influenza in Florence to isolate the virus 
in Vero cells, but were unsuccessful. 
Identification of close contacts
According to a standard definition of ‘close contact’ [3], 
115 contacts of this patient were identified and placed 
under surveillance: 90 in the healthcare setting (14 
healthcare workers (HCWs) in Hospital A, two HCWs of 
the local health district (ASL 10) of Florence, 28 HCWs of 
Hospital B, one patient who shared the same hospital 
room (before the index case was placed in isolation), 
five cleaners of Hospital B, who worked in the room 
of the index case (before he was placed in isolation) 
and three ambulance operators); in addition, the sur-
veillance included 37 patients who attended the emer-
gency room in Hospital A at the same time of the index 
case); four family members; nine from the aeroplane 
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(the names of the passengers who were on the same 
return flight of the index case, with an assigned seat in 
the same row and in the two rows in front and behind 
him, were easily obtained but the exact position of 
these contacts on the plane was difficult to assess as 
some passengers could have changed their assigned 
seats); and 12 at the patient’s place of work.) However, 
it must be underlined that, although particular atten-
tion was given to people who had had prolonged face-
to-face contact with the index case (duration of at least 
15 minutes within one metre from the confirmed case), 
some of the above 115 individuals placed under clinical 
surveillance, mainly from the healthcare setting, may 
have had a lesser degree of contact with him or were 
already wearing personal protective equipment at the 
time of contact.
Cases 2 and 3
On 29 May, the index case’s relation (Case 2) aged 
about a year and a half developed a mild febrile illness 
(Figure). She had been in close contact with the index 
case on May 26, when the man spent all the day with 
her and her family, staying in the same room. As she 
was under surveillance, she was admitted to a chil-
dren’s hospital (Hospital C) in Florence, on 31 May and 
a nasopharyngeal swab was taken. This tested positive 
for MERS-CoV, by real-time PCR for the upE region, the 
following day. Five family members of the child under-
went clinical surveillance. 
On 31 May, a female co-worker of the index case (Case 
3), in her early 40s, who shared the same office with 
the index case on 27 May,  developed influenza-like 
illness (fever (37.5 °C )and cough) (Figure). She was 
admitted to the Infectious Diseases Unit of Hospital 
B in Florence on 1 June and a nasopharyngeal swab 
tested positive for MERS-CoV, by real-time PCR for the 
upE region, the same day. Her five family members 
(husband, three sons and her father) were also placed 
under clinical surveillance. A further three close con-
tacts (two friends and a family general practitioner) 
were identified: these eight contacts plus 16 work col-
leagues were monitored clinically, bringing the total 
number of Case 3’s contacts placed under surveillance 
to 24. 
As for the index case, the nasopharyngeal swabs of 
Cases 2 and 3 were tested for MERS-CoV by real time 
PCR for the upE gene [1]. According to guidance docu-
ments of the World Health Organization (WHO) [4], 
these laboratory results were interpreted as ‘presump-
tive’ evidence of MERS-CoV infection in both cases. 
The final classification as confirmed cases was given 
on the basis of laboratory data combined with clinical/
epidemiological information available. 
Case definition and clinical 
surveillance of contacts
In Italy, a possible case of MERS-CoV infection is 
defined as follows:
Figure
Timeline of three cases of Middle East Respiratory 
Syndrome Coronavirus (MERS-CoV) infection, Italy, 24 
May–6 June 2013
NPS: nasopharyngeal swab.
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•	 any patient with an acute respiratory infection, 
which may include history of fever (≥38 °C) and 
cough and indications of pulmonary parenchymal 
disease (e.g. pneumonia or acute respiratory dis-
tress syndrome (ARDS)), AND 
•	 whose illness cannot be explained by the presence 
of other infections, AND 
•	 who had a history of travel to or residence in 
affected areas (in the Middle East), during the 10 
days before symptom onset, OR 
•	 having had close contact, during the 10 days before 
symptom onset, with a symptomatic confirmed 
case of MERS-CoV infection. 
On the basis of WHO and ECDC guidance documents 
[5,6], a probable case of MERS-CoV infection is defined 
as follows:
•	 a person with a febrile acute respiratory illness with 
clinical, radiological or histopathological evidence 
of pulmonary parenchymal disease (e.g. pneumo-
nia or ARDS), AND 
•	 for whom MERS-CoV infection has not been labora-
tory confirmed, AND 
•	 who has no direct epidemiological link to a con-
firmed MERS-CoV case. 
A confirmed case is defined as a person with labora-
tory confirmation of MERS-CoV infection [5,6].
According to national guidelines [7], for each possible 
case, clinical samples from the upper respiratory tract 
(nasopharyngeal swabs), as well as lower respiratory 
specimens (sputum or bronchoalveolar lavage fluid, 
when possible), have to be collected and tested for 
MERS-CoV in an initial screen by the regional reference 
laboratory; positive results have to be confirmed by 
the National Influenza Centre at ISS.
As soon as the index case was suspected to be infected 
with MERS-CoV, exposed individuals were identified 
through contact tracing and a clinical surveillance 
protocol was followed. All contacts were followed up 
during a 10-day period (i.e. the maximum incubation 
period, according to the knowledge of the disease at 
the time of the investigation described in this report) 
[5] after their last contact with the index case, to check 
if symptoms appeared. Particular attention was given 
to people who had had prolonged face-to-face contact 
with the index case (duration of at least 15 minutes 
within one metre from the confirmed case). 
Discussion
As of 1 August 2013, 94 laboratory-confirmed cases 
of MERS-CoV infection have been reported worldwide 
since the first detection of this novel virus in Saudi 
Arabia in 2012, including 46 deaths [8]. 
In this report, we present the investigation of the first 
case of MERS-CoV diagnosed in Italy and also present 
evidence of limited person-to-person transmission of 
MERS-CoV, to two people who had close contact with 
the symptomatic index case when he was back in Italy 
and who had not previously travelled abroad. Both sec-
ondary cases were classified as confirmed on the basis 
of a combination of clinical (influenza-like illness), 
epidemiological (close contact with the index case) 
and laboratory data, according to WHO guidelines [4]. 
Nasopharyngeal swabs of both secondary cases tested 
positive only in the screening assay (real-time PCR to 
detect the regions upstream of the E gene), probably 
due to the known limitations when using upper respira-
tory tract specimens [5,9]. Although required [7], lower 
respiratory tract specimens were not available.
It must be underlined that the index case was a pre-
viously healthy middle-age man, who developed fever 
and respiratory symptoms on 24 May, i.e. the day 
before his travel from Jordan to Italy.  For the two sec-
ondary cases, the putative incubation time (i.e. days 
from putative exposure to symptom onset) was 3-4 
days, according to data already reported [10,11]. The 
incubation period was somewhat shorter than that 
found for the Severe Acute Respiratory Syndrome 
(SARS)-coronavirus infection [12].  
All three patients, including the index case who devel-
oped pneumonia, fully recovered in less than two 
weeks after symptom onset, unlike most of the MERS-
CoV severe cases reported [10,11].  Nevertheless, it 
should be stressed that none of the three patients had 
underlying clinical conditions. In this regard, it is also 
important to highlight recent findings [10] that sug-
gested the disease is milder in people who were identi-
fied through contact tracing, compared with that seen 
in those presenting with symptoms.
None of the other 144 contacts monitored (115 for the 
index case, 5 for Case 2 and 24 for Case 3) developed 
fever or other symptoms suggestive of an acute res-
piratory illness after 10 days’ follow-up. Respiratory 
specimens have been collected from 70 of the contacts 
and have tested negative for MERS-CoV.
As useful additional information can be obtained from 
serological investigations, we will analyse sera col-
lected from the three cases. Furthermore, although 
rapid contact tracing was undertaken, identification 
and follow-up of a larger number of contacts and the 
collection of serum samples would be of great value, to 
better determine the potential presence of subclinical 
infections. Notably, an increasing proportion of peo-
ple with asymptomatic infection have been recently 
reported [9,13], through contact tracing among close 
contacts of cases.
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